Ardelyx, Inc.
NASDAQ:ARDX · NASDAQ Global Market
-$0.06 today
Vol 9.83M · Avg 3.58M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ARDX · Revenue to Net Income
Key Ratios
Analysis
$427.7M of revenue converted into -$58.1M of net income for the selected period. Gross margin is 91.9% and net margin is -15.1%, showing how much revenue survives after costs and taxes. EPS is $-0.24, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $407.3M +22.1% | $333.6M +168.1% | $124.5M +138.6% | $52.2M +416.6% | $10.1M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $42.6M -15.7% | $50.6M +184.1% | $17.8M +332.2% | $4.1M +311.7% | $1.0M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $364.7M +28.9% | $283.1M +165.4% | $106.7M +122.0% | $48.0M +428.1% | $9.1M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 89.5% +4.7pp | 84.8% -0.9pp | 85.7% -6.4pp | 92.1% +2.0pp | 90.1% | 9.8% | 28.9% | 38.3% |
| Research & Development | $68.5M +30.9% | $52.3M +47.2% | $35.5M +1.0% | $35.2M -61.4% | $91.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $337.2M +30.4% | $258.7M +92.5% | $134.4M +75.5% | $76.6M +5.9% | $72.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $405.7M +30.4% | $311.0M +83.0% | $169.9M +52.0% | $111.8M -31.6% | $163.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $3.1M +48.3% | $2.1M +59.7% | $1.3M +12.9% | $1.1M -59.2% | $2.8M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$29.2M -74.6% | -$16.7M +69.8% | -$55.4M +9.2% | -$61.0M +59.6% | -$150.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -7.2% -2.2pp | -5.0% +39.5pp | -44.5% +72.4pp | -116.9% +1377.1pp | -1494.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$41.0M -46.6% | -$27.9M +55.8% | -$63.3M +0.8% | -$63.8M +58.7% | -$154.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -10.1% -1.7pp | -8.4% +42.5pp | -50.8% +71.4pp | -122.2% +1406.4pp | -1528.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $28.4M +41.3% | $20.1M +126.4% | $8.9M +74.9% | $5.1M +12.7% | $4.5M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$19.7M -80.0% | -$10.9M -386.6% | -$2.2M +34.8% | -$3.4M +9.8% | -$3.8M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$60.6M -56.0% | -$38.9M +40.7% | -$65.5M +2.5% | -$67.2M +57.5% | -$158.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -14.9% -3.2pp | -11.7% +41.0pp | -52.6% +76.2pp | -128.8% +1437.6pp | -1566.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $969.0K +264.3% | $266.0K -51.4% | $547.0K +6737.5% | $8.0K +100.0% | $4.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$61.6M -57.4% | -$39.1M +40.8% | -$66.1M +1.7% | -$67.2M +57.5% | -$158.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | -15.1% -3.4pp | -11.7% +41.4pp | -53.1% +75.8pp | -128.9% +1437.6pp | -1566.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 -52.9% | -$0 +43.3% | -$0 +28.6% | -$0 +72.4% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 -52.9% | -$0 +43.3% | -$0 +28.6% | -$0 +72.4% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $241.0M +2.5% | $235.2M +7.3% | $219.3M +38.2% | $158.7M +52.3% | $104.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $241.0M +2.5% | $235.2M +7.3% | $219.3M +38.2% | $158.7M +52.3% | $104.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$5.31B
Trevi Therapeutics, Inc.
NASDAQ:TRVI
$2.39B
Pharvaris N.V.
NASDAQ:PHVS
$2.28B
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
$1.91B
Stoke Therapeutics, Inc.
NASDAQ:STOK
$1.87B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.69B
Zymeworks Inc.
NASDAQ:ZYME
$1.68B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.39B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.17B
Upstream Bio, Inc.
NASDAQ:UPB
$337.95M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ARDX generate?
Ardelyx, Inc. (ARDX) reported $407.32M of revenue in fiscal 2025.
Is ARDX profitable?
Ardelyx, Inc. (ARDX) reported -$61,599,000.00 of net income, with a net margin of -15.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.